The world’s first RNA therapeutic Nexturn Bio has completed its first investment review for a new miRNA pharmaceutical company in the United States
Nexturn Bio Inc., a subsidiary of South Korea-based Nexturn Bioscience Co., Ltd., has selected its first technology investment destination to expand its new organic business. Nexturn Bio announced that it has acquired a 50% interest in RosVivo Therapeutics, Inc. as a final investment target with the support of its parent company Nexturn Bioscience Co., Ltd. has secured. RosVivo, which is to receive an investment from Nexturn Bio Inc., is a research and development company for miRNA (microRNA) new drugs in Nevada.
While RNA vaccine development has been in the spotlight since the Corona-19 outbreak, RSVI-301, RosVivo’s new drug pipeline for diabetes, also uses miRNA (micro-RNA). MiRNA consists of 20 to 24 nucleotides and is known as a “little cleaner” in the body that naturally regulates the metabolic processes of genes and proteins. Because these miRNA treatments inject human-derived genetic material, they are expected to have a higher stability value than traditional mRNA treatments that use external genetic materials such as viruses.
In particular miR-10-5p The study on which the new drug development is based enables researchers to observe the world’s first beta cell regeneration of the pancreas. Nexturn Bio Inc. and RosVivo Therapeutics, Inc. said so will appoint Scientific Advisory Board (SAB) for thorough review as it is an important precedent for diabetes research. The counselors are in several large national hospitals like that Stanford University of Medicine to support professional advice throughout drug development.
Nexturn Bio Inc. plans to achieve both “innovation” and “marketability” with RosVivo’s new miRNA drug. It was reported that CEO Song Myung-Seok took part discover Candidates in founding a subsidiary. “RosVivo is Nexturn Bio’s first official investment, and RosVivo’s RSVI-301 will be an innovative opportunity to usher in a new era of mRNA medicine and challenge the complete cure for diabetes,” said the CEO.
Caption – miR-10-5p is a key factor in GI dysmotility and diabetes via the KLF11-KIT pathway